Top member reports
Consensus community valuation
Contributing Members
Sort by:
Recent
Create your free Strawman account to view member valuations
#ASX Announcements
Added a month ago

POSITIVE RESULTS FROM EVALUATION OF EXO-NET IN PANCREATIC CANCER

  • Pancreatic cancer is one of the most deadly cancers, with a 5-year survival rate of 10%
  • No liquid biopsy tests exist for the early detection of pancreatic cancer
  • Positive results from collaborative research study to evaluate BARD1’s EXO-NET™ exosome capture technology and Minomic’s anti-GPC-1 antibody for detection of pancreatic cancer
  • EXO-NET™ was shown to isolate exosomes from pancreatic cancer patients and healthy control plasma samples
  • Minomic’s GPC-1 antibody was shown to specifically bind EXO-NET isolated pancreatic cancer exosomes and not bind healthy (non-cancer) exosomes
  • Pilot study demonstrates the scientific feasibility of utilising EXO-NET™ to isolate exosomes for pancreatic cancer detection in conjunction with an anti-GPC-1 antibody

View Attachment

Read More
#Test Data 15/2/21
Added 2 months ago

EXCELLENT SUBB2M BREAST CANCER TEST DATA

• Griffith University releases additional data on BARD1’s SubB2M technology showing 100% specificity and over 95% sensitivity for detection of all stages of breast cancer

• BARD1 aims to develop and commercialise SubB2M-based blood tests for breast cancer to enable earlier detection, inform treatment decisions and improve women’s health outcomes

View Attachment

Read More
#TEST RESULT 11/2/21
Added 2 months ago

OUTSTANDING SUBB2M OVARIAN CANCER TEST DATA

~ Griffith University releases data on BARD1’s SubB2M technology showing 100% specificity and sensitivity for detection of all stages of ovarian cancer

~ Paper presenting this data at the Australia New Zealand Gynaecological Oncology Group (ANZGOG) Conference 2021

Melbourne, Australia, 11 February 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that Griffith University’s Institute of Glycomics has released data showing that SubB2M can be used to detect all stages of ovarian cancer with 100% specificity and 100% sensitivity.

SubB2M is a protein that binds specifically to a sugar molecule called Neu5Gc which is present on a range of cancers. In humans, Neu5Gc is only found on human tumour cells and tumour-associated molecules, potentially making Neu5Gc a highly specific pan-cancer biomarker. BARD1 holds the exclusive worldwide license for the use of SubB2M to detect any cancer.

 

View Attachment

Read More